1.63

0.61% -0.01

Pre-market: 1.65 0.02 +1.23%

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $1.63, with a volume of 410.39K. It is down -0.61% in the last 24 hours and down -4.68% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Previous Close:

$1.64

Open:

$1.63

24h Volume:

410.39K

Relative Volume:

0.78

Market Cap:

$171.74M

Revenue:

$17.91M

Net Income/Loss:

$-47.66M

P/E Ratio:

-3.5856

EPS:

-0.4546

Net Cash Flow:

$-62.63M

1W Performance:

+10.14%

1M Performance:

-4.68%

6M Performance:

-31.51%

1Y Performance:

-9.44%

1-Day Range:

$1.59

$1.6973

1-Week Range:

$1.43

$1.6973

52-Week Range:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

Address

Employee

187

Twitter

@proqr

Next Earnings Date

2026-05-14

Latest SEC Filings

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRQR Proqr Therapeutics N V	1.63	171.74M	17.91M	-47.66M	-62.63M	-0.4546
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Oppenheimer	Outperform
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight
Apr-29-25	Initiated	Evercore ISI	Outperform
Mar-10-25	Upgrade	Citigroup	Neutral → Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

May 05, 2026

ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail

May 05, 2026

ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN

May 05, 2026

May 04, 2026

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 - markets.businessinsider.com

May 04, 2026

ProQR Therapeutics NV expected to post a loss of 12 cents a shareEarnings Preview - TradingView

May 04, 2026

ProQR Therapeutics N : AGM 2026 POA Registered Shareholders - marketscreener.com

May 04, 2026

ProQR sets June 2 shareholder meeting, posts agenda documents online - Stock Titan

May 04, 2026

ProQR (PRQR) 2026 AGM to expand share capital, issuance and buyback powers - Stock Titan

May 04, 2026

May 03, 2026

MSN Money - MSN

May 03, 2026

May 01, 2026

ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase - The Globe and Mail

May 01, 2026

Apr 30, 2026

ProQR nominates Boehringer Ingelheim executive to board - Investing.com UK

Apr 30, 2026

ProQR nominates Boehringer Ingelheim executive to board By Investing.com - Investing.com Australia

Apr 30, 2026

Boehringer exec tapped for ProQR (NASDAQ: PRQR) board nomination - Stock Titan

Apr 30, 2026

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors - GlobeNewswire

Apr 30, 2026

Apr 29, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in April - MarketBeat

Apr 29, 2026

Apr 27, 2026

ProQR Therapeutics NV (MEX:PRQRN) Stock News, Headlines & Updates - GuruFocus

Apr 27, 2026

ProQR Therapeutics NV (MEX:PRQRN) Stock Price & 30 Year Financial Data - GuruFocus

Apr 27, 2026

Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation - MSN

Apr 27, 2026

Apr 26, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 26, 2026

Apr 25, 2026

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Apr 25, 2026

Apr 22, 2026

ProQR Therapeutics NV (MEX:PRQRN) Short-term investments - GuruFocus

Apr 22, 2026

Apr 18, 2026

ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus

Apr 18, 2026

ProQR Therapeutics NV (MEX:PRQRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Apr 18, 2026

Apr 16, 2026

Jobs Data: Can ProQR Therapeutics NV withstand a market correctionQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn

Apr 13, 2026

Stock Analysis: Can ProQR Therapeutics NV outperform under higher oil prices2026 Short Interest & Precise Trade Entry Recommendations - baoquankhu1.vn

Apr 13, 2026

Volume Report: Is ProQR Therapeutics NV currently under institutional pressure2026 Gainers & Expert Verified Movement Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan

Apr 11, 2026

Apr 10, 2026

ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha

Apr 10, 2026

Apr 09, 2026

PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus

Apr 09, 2026

Proqr Therapeutics expands early-stage pipeline - BioWorld News

Apr 09, 2026

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital - MarketBeat

Apr 09, 2026

ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter - Defense World

Apr 09, 2026

Aberdeen Group Boosts Stake in ProQR Therapeutics - National Today

Apr 09, 2026

Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat

Apr 09, 2026

ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs - The Globe and Mail

Apr 09, 2026

Apr 08, 2026

ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus

Apr 08, 2026

ProQR partners with Ginkgo on AI drug discovery platform By Investing.com - Investing.com Australia

Apr 08, 2026

ProQR updates RNA editing pipeline, targets biliary atresia By Investing.com - Investing.com Australia

Apr 08, 2026

ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI

Apr 08, 2026

ProQR updates RNA editing pipeline, targets biliary atresia - Investing.com

Apr 08, 2026

Pipeline expansion and cash runway into 2027 for ProQR (PRQR) - Stock Titan

Apr 08, 2026

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event - Weekly Voice

Apr 08, 2026